ARTICLE | Clinical News

GS 840 data

May 1, 1995 7:00 AM UTC

GILD (Foster City, Calif.) reported Phase I/II results showing safety and a drug-related, statistically significant decrease in p24 antigen over the two weeks of the trial (p=0.005 for all treated patients compared to placebo).

The drug was given once a day. Side effects were mild to moderate gastrointestinal symptoms. As presented at the Conference on Antiviral Research in Santa Fe, 36 patients with CD4 counts >100 received either 125, 250, or 500 mg or placebo. ...